Abdul Latif Jameel

Abdul Latif Jameel is a privately held, internationally diversified business group founded in Saudi Arabia in 1945, with operations spanning mobility, financial services, energy, real estate, investment, and health. The requested entity name refers primarily to the parent conglomerate rather than a pure-play biotech or pharmaceutical company. Its healthcare activities are conducted mainly through Abdul Latif Jameel Health and Abdul Latif Jameel Hospital, which focus on healthcare access, commercialization and distribution partnerships, medical devices, specialty and rare-disease market access, and rehabilitation services across the Middle East, Africa, Turkey, and broader Global South. The group has announced partnerships involving Butterfly Network, EQRx, Cyberdyne, Evelo Biosciences, Melody International, and Holoeyes, and Abdul Latif Jameel Health acquired a majority stake in Genpharm in 2024. For biotech diligence purposes, Abdul Latif Jameel is best characterized as a diversified private business group with a healthcare commercialization and access arm, not a drug developer with an internal R&D pipeline.